SequelSEC

Dare Bioscience, Inc. DARE

Pharmaceutical Preparations · CIK 0001401914 · Fiscal year ends 1231

Revenue
$1.37M
Fiscal year ended 2026-06-30
Operating income
-$11.11M
Fiscal year ended 2026-06-30
Free cash flow
-$11.76M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$21.34MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.47Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue20.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity7.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth10429.4%99th
CapEx / revenue37.4%89th
Current ratio1.14x18th
FCF margin-997.0%24th
SBC / revenue145.3%73th
Net margin-1300.7%28th
Operating margin-1315.5%31th
R&D / revenue536.1%66th
Gross margin71.3%50th

Dare Bioscience, Inc. (DARE) reported revenue of $1.37M and net income of -$10.99M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Dare Bioscience, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Dare Bioscience, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.37M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$11.11M
Net income-$10.99M
Research & development$2.70M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Dare Bioscience, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$12.62M
Total assets$22.37M
Current assets$16.69M
Total liabilities$22.93M
Current liabilities$16.92M
Total equity incl. NCI-$560.10K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$762.91K

Cash flow

Dare Bioscience, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$11.29M
Capital expenditures$461.93K
Investing cash flow-$461.93K
Financing cash flow$19.31M
Net change in cash$7.58M
Stock-based compensation$1.50M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.13M

Derived

Dare Bioscience, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$11.76M
Gross marginUnavailable
Operating margin-813.4%
FCF margin-860.6%
SBC / revenue110.0%
Current ratio0.99x
Revenue YoY growthUnavailable
Net margin-804.4%
R&D / revenue197.6%
CapEx / revenue33.8%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DARE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.